Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 7, 2015, Pages 1167-1174

  Xing, Minzhi ^a   Webber, Grant ^c   Prajapati, Hasmukh J ^c   Chen, Zhengjia ^e   El Rayes, Bassel ^c   Spivey, James R ^d   Pillai, Anjana A ^d   Kim, Hyun S ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY HOSPITAL   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

Hepatocellular carcinoma; Quality of life; Transarterial chemoembolization

Indexed keywords

DOXORUBICIN; ANTINEOPLASTIC ANTIBIOTIC;

ADULT; ARTICLE; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CONTROLLED STUDY; ETHNICITY; FEMALE; FOLLOW UP; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRESERVATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SCORING SYSTEM; SHORT FORM 36; UNRESECTABLE HEPATOCELLULAR CARCINOMA; AGED; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PROCEDURES; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVIVAL RATE;

EID: 84931072387     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12920     Document Type: Article

References (32)

1. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin. Liver Dis. 2005; 9: 191-211.
2. Toro A, Pulvirenti E, Palermo F, Di Carlo I. Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment. Surg. Oncol. 2012; 21: e23-30.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 69-90.
4. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
6. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J. Gastroenterol. 2009; 15: 3210-3216.
7. Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am. J. Clin. Oncol. 1998; 21: 386-391.
8. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 1999; 19: 329-338.
9. Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am. J. Gastroenterol. 2005; 100: 1995-2004.
10. Lammer J, Malagari K, Vogl T etal. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc. Intervent. Radiol. 2010; 33: 41-52.
11. Golfieri R, Giampalma E, Renzulli M etal. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br. J. Cancer 2014; 111: 255-264.
12. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J. Surg. Oncol. 2010; 101: 476-480.
13. Sacco R, Bargellini I, Bertini M etal. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J. Vasc. Interv. Radiol. 2011; 22: 1545-1552.
14. Huang K, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2014; 29: 920-925.
15. Prajapati HJ, Dhanasekaran R, El-Rayes BF etal. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. J. Vasc. Interv. Radiol. 2013; 24: 307-315.
16. Prajapati HJ, Rafi S, El-Rayes BF, Kauh JS, Kooby DA, Kim HS. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization. J. Vasc. Interv. Radiol. 2012; 23: 1286-1931.
17. Jongen PJ, Lehnick D, Sanders E etal. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health Qual. Life Outcomes 2010; 8: 133-139.
18. Fan SY, Eiser C, Ho MC. Health-related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin. Gastroenterol. Hepatol. 2010; 8: 559-64.e10.
19. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992; 30: 473-483.
20. Wible BC, Rilling WS, Drescher P etal. Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J. Vasc. Interv. Radiol. 2010; 21: 1024-1030.
21. Salem R, Gilbertsen M, Butt Z etal. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin. Gastroenterol. Hepatol. 2013; 11: 1358-1651.
22. Steel JL. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann. Oncol. 2006; 17: 304-312.
23. Sun V, Ferrell B, Juarez G, Wagman LD, Yen Y, Chung V. Symptom concerns and quality of life in hepatobiliary cancers. Oncol. Nurs. Forum 2008; 35: E45-52.
24. Steel J, Baum A, Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere®). Psychooncology 2004; 13: 73-79.
25. DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general self-rated health question. A meta-analysis. J. Gen. Intern. Med. 2006; 21: 267-275.
26. Kondo Y, Yoshida H, Tateishi R etal. Health-related quality of life of chronic liver disease patients with and without hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2007; 22: 197-203.
27. Kalva SP, Pectasides M, Liu R etal. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc. Intervent. Radiol. 2014; 37: 381-387.
28. Burrel M, Reig M, Forner A etal. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J. Hepatol. 2012; 56: 1330-1335.
29. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study. HPB 2010; 12: 174-180.
30. Song MJ, Chun HJ, Song DS etal. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J. Hepatol. 2012; 57: 1244-1250.
31. Vogl TJ, Lammer J, Lencioni R etal. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am. J. Roentgenol. 2012; 197: W562-570.
32. Ring L, Hofer S, Heuston F, Harris D, O'Boyle CA. Response shift masks the treatment impact on patient reported outcomes (PROs): the example of individual quality of life in edentulous patients. Health Qual. Life Outcomes 2005; 3: 55-62.